Dyne Therapeutics, Inc.
DYN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818794
In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Dyne Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 10 filings
- 6 insiders, $90.2M in total
- Insiders trading
- 6
- Net value
- −$90.2M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Dyne Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer | 152,897 | Sep 8, 2026 | 7 |
| Kerr Douglas | Chief Medical Officer | 162,564 | Sep 8, 2026 | 7 |
| Cox John | CEO & President | 357,507 | Sep 8, 2026 | 7 |
| Rhodes Jason P | Director | 428,946Indirect | Aug 17, 2026 | 9 |
| Lucera Erick | Chief Financial Officer | 119,766 | Aug 17, 2026 | 5 |
| Kersten Dirk | Director | 3,586,796Indirect | Jul 29, 2026 | 9 |
| Greene Barry E | Director | – | Jun 23, 2026 | 1 |
| Hurwitz Edward | Director | – | Jun 9, 2026 | 1 |
| Posner Brian S | Director | 24,500 | Jun 9, 2026 | 8 |
| Lubner David Charles | Director | 0 | Jun 9, 2026 | 2 |
| Stehman-Breen Catherine | Director | – | Jun 9, 2026 | 1 |
| Incerti Carlo | Director | 0 | Jun 9, 2026 | 1 |
| Karnani Vikram | Director | – | Dec 23, 2025 | 1 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 122,330 | Mar 13, 2025 | 0 |
| Beskrovnaya Oxana | Chief Scientific Officer | 195,840 | Mar 13, 2025 | 0 |
| High Susanna Gatti | Chief Operating Officer | 131,636 | Sep 19, 2024 | 0 |
| McNeill Jonathan | Chief Business Officer | 132,106 | Aug 20, 2024 | 0 |
| Farwell Wildon | Chief Medical Officer | 143,222 | Aug 20, 2024 | 0 |
| Brumm Joshua T | CEO & President | 537,998 | Mar 12, 2024 | 0 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Opportunity Fund II, L.P. | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Associates Opportunity II, LLC | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Associates Opportunity II, LP | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 864,487Indirect | Feb 28, 2024 | 0 |
| Atlas Venture Associates XI, LLC | 10% Owner | 864,487Indirect | Feb 28, 2024 | 0 |
| Atlas Venture Associates XI, L.P. | 10% Owner | 864,487Indirect | Feb 28, 2024 | 0 |
| Klein Lawrence Otto | Director | – | Jul 6, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | Beskrovnaya OxanaChief Scientific Officer | SSale | −1.44K | $15.90 | −$23.0K | −7.5%17.8K after | 2 lots |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | Brumm Joshua TSee Remarks | SSale | −8.01K | $15.90 | −$127.3K | −7.5%99.0K after | 2 lots |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | McNeill JonathanSee Remarks | SSale | −1.27K | $15.90 | −$20.3K | −3.5%35.6K after | 2 lots |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | Scalzo Richard WilliamSee Remarks | SSale | −859 | $15.90 | −$13.7K | −7.5%10.6K after | 2 lots |
| Sep 24, 2021 (view filing) | Sep 23 | 1 day | High Susanna GattiChief Operating Officer | SSale | −2.45K | $17.22 | −$42.2K | −6.8%33.5K after | |
| Mar 3, 2022 (view filing) | Mar 2 | 1 day | Farwell WildonChief Medical Officer | SSale | −5.62K | $8.56 | −$48.1K | −7.8%66.7K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Beskrovnaya OxanaChief Scientific Officer | SSale | −693 | $8.73 | −$6.05K | −1.3%53.7K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Brumm Joshua TSee Remarks | SSale | −3.38K | $8.73 | −$29.5K | −1.6%210.3K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Farwell WildonChief Medical Officer | SSale | −640 | $8.73 | −$5.59K | −1.0%66.0K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | High Susanna GattiChief Operating Officer | SSale | −765 | $8.73 | −$6.68K | −1.0%73.0K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | McNeill JonathanSee Remarks | SSale | −481 | $8.73 | −$4.20K | −0.8%60.5K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Scalzo Richard WilliamSee Remarks | SSale | −308 | $8.73 | −$2.69K | −1.1%27.0K after | |
| Oct 11, 2022 (view filing) | Oct 7-10 | 4 days | Brumm Joshua TSee Remarks | SSale | −210.0K | $12.52 | −$2.63M | −50.6%204.6K after | 2 lots |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | Beskrovnaya OxanaChief Scientific Officer | SSale | −680 | $10.87 | −$7.39K | −0.7%90.1K after | |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | Brumm Joshua TSee Remarks | SSale | −3.32K | $10.87 | −$36.1K | −1.0%329.8K after | |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | Farwell WildonChief Medical Officer | SSale | −628 | $10.87 | −$6.83K | −0.6%100.1K after | |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | High Susanna GattiChief Operating Officer | SSale | −751 | $10.87 | −$8.16K | −0.7%112.0K after | |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | McNeill JonathanSee Remarks | SSale | −472 | $10.87 | −$5.13K | −0.5%97.8K after | |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | Scalzo Richard WilliamSee Remarks | SSale | −312 | $10.87 | −$3.39K | −0.6%56.2K after | |
| Dec 14, 2022 (view filing) | Dec 12 | 2 days | Rhodes Jason PDirector | PPurchase | +934.6K | $10.70 | +$10.0M | New position934.6K after | |
| Dec 14, 2022 (view filing)4:55 PM ET | Dec 12 | 2 days | Atlas Venture Fund XI, L.P. and 8 others10% Owner | PPurchase | +934.6K | $10.70 | +$10.0M | New position934.6K after | Duplicate filing |
| Jan 11, 2023 (view filing) | Jan 9 | 2 days | McNeill JonathanSee Remarks | SSale | −30.1K | $11.57 | −$348.8K | −30.8%67.6K after | |
| Jan 23, 2023 (view filing) | Jan 18 | 5 daysLate | McNeill JonathanSee Remarks | SSale | −10.0K | $14.03 | −$140.3K | −12.9%67.6K after | |
| Mar 15, 2023 (view filing) | Mar 14 | 1 day | Beskrovnaya OxanaChief Scientific Officer | SSale | −1.42K | $13.33 | −$18.9K | −1.6%88.7K after | |
| Mar 15, 2023 (view filing) | Mar 14 | 1 day | Brumm Joshua TSee Remarks | SSale | −7.32K | $13.33 | −$97.5K | −2.2%322.5K after | |
| Mar 15, 2023 (view filing) | Mar 14 | 1 day | Farwell WildonChief Medical Officer | SSale | −7.44K | $13.33 | −$99.2K | −7.4%92.7K after | |
| Mar 15, 2023 (view filing) | Mar 14 | 1 day | High Susanna GattiChief Operating Officer | SSale | −1.56K | $13.33 | −$20.8K | −1.4%110.5K after | |
| Mar 15, 2023 (view filing) | Mar 13-14 | 2 days | McNeill JonathanSee Remarks | SSale | −2.21K | $13.18 | −$29.1K | −3.3%65.4K after | 2 lots |
| Mar 15, 2023 (view filing) | Mar 14 | 1 day | Scalzo Richard WilliamSee Remarks | SSale | −1.31K | $13.33 | −$17.5K | −2.3%54.9K after | |
| Jun 12, 2023 (view filing) | Jun 8-12 | 4 days | Brumm Joshua TSee Remarks | SSale | −325.3K | $12.90 | −$4.20M | −56.2%253.4K after | 4 lots |
| Jun 14, 2023 (view filing) | Jun 13 | 1 day | Beskrovnaya OxanaChief Scientific Officer | SSale | −1.48K | $12.43 | −$18.3K | −1.7%87.3K after | |
| Jun 14, 2023 (view filing) | Jun 13 | 1 day | Farwell WildonChief Medical Officer | SSale | −1.70K | $12.43 | −$21.1K | −1.8%91.0K after | |
| Jun 14, 2023 (view filing) | Jun 13 | 1 day | High Susanna GattiChief Operating Officer | SSale | −1.63K | $12.43 | −$20.2K | −1.5%108.9K after | |
| Jun 14, 2023 (view filing) | Jun 12-13 | 2 days | McNeill JonathanSee Remarks | SSale | −2.26K | $12.68 | −$28.6K | −3.5%63.1K after | 2 lots10b5-1 |
| Jun 15, 2023 (view filing) | Jun 13-15 | 2 days | Scalzo Richard WilliamSee Remarks | SSale | −51.4K | $12.71 | −$653.2K | −54.2%43.5K after | 3 lots |
| Sep 13, 2023 (view filing) | Sep 12 | 1 day | Beskrovnaya OxanaChief Scientific Officer | SSale | −1.48K | $10.41 | −$15.4K | −1.7%85.8K after | |
| Sep 13, 2023 (view filing) | Sep 12 | 1 day | Brumm Joshua TSee Remarks | SSale | −7.67K | $10.41 | −$79.9K | −3.0%245.7K after | |
| Sep 13, 2023 (view filing) | Sep 12 | 1 day | High Susanna GattiChief Operating Officer | SSale | −1.64K | $10.41 | −$17.0K | −1.5%107.2K after | |
| Sep 13, 2023 (view filing) | Sep 12 | 1 day | McNeill JonathanChief Business Officer | SSale | −1.27K | $10.41 | −$13.2K | −2.0%61.9K after | 10b5-1 |
| Sep 13, 2023 (view filing) | Sep 12 | 1 day | Scalzo Richard WilliamSee Remarks | SSale | −1.40K | $10.41 | −$14.5K | −3.2%42.1K after | |
| Sep 13, 2023 (view filing) | Sep 12 | 1 day | Farwell WildonChief Medical Officer | SSale | −1.71K | $10.41 | −$17.8K | −1.9%89.3K after | |
| Sep 20, 2023 (view filing) | Sep 18 | 2 days | Beskrovnaya OxanaChief Scientific Officer | SSale | −1.44K | $9.41 | −$13.5K | −1.7%84.3K after | |
| Sep 20, 2023 (view filing) | Sep 18 | 2 days | Brumm Joshua TSee Remarks | SSale | −12.0K | $9.41 | −$113.2K | −4.9%233.7K after | |
| Sep 20, 2023 (view filing) | Sep 18 | 2 days | High Susanna GattiChief Operating Officer | SSale | −2.67K | $9.41 | −$25.1K | −2.5%104.5K after | |
| Sep 20, 2023 (view filing) | Sep 18 | 2 days | McNeill JonathanChief Business Officer | SSale | −1.26K | $9.41 | −$11.9K | −2.0%60.6K after | |
| Sep 20, 2023 (view filing) | Sep 18 | 2 days | Scalzo Richard WilliamSee Remarks | SSale | −1.29K | $9.41 | −$12.1K | −3.1%40.8K after | |
| Nov 2, 2023 (view filing) | Nov 2 | Same day | High Susanna GattiChief Operating Officer | SSale | −9.94K | $7.40 | −$73.5K | −9.5%94.6K after | |
| Dec 6, 2023 (view filing) | Dec 4-6 | 2 days | Scalzo Richard WilliamSee Remarks | SSale | −2.55K | $12.01 | −$30.7K | −2.0%128.0K after | 2 lots10b5-1 |
| Dec 12, 2023 (view filing) | Dec 11 | 1 day | Beskrovnaya OxanaChief Scientific Officer | SSale | −1.47K | $10.72 | −$15.7K | −0.8%176.6K after | |
| Dec 12, 2023 (view filing) | Dec 11 | 1 day | Brumm Joshua TSee Remarks | SSale | −7.58K | $10.72 | −$81.3K | −1.3%585.0K after |